Categories: NewsPharmaceutical

Oculis updates share capital for its existing at-the-market offering program

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

ZUG, Switzerland, Jan. 31, 2025 (GLOBE NEWSWIRE) — Oculis Holding AG (Nasdaq: OCS; XICE: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company, has issued registered ordinary shares of the Company, each with a nominal value of CHF 0.01, issued out of existing capital band (Kapitalband), for an aggregate of 2,500,000 ordinary shares of the Company (the “New Shares”), recorded as treasury shares. The number of registered shares issued by the Company as per its Articles of Association is 48,943,700, of which approximately 43 million shares are outstanding. Following the issuance, the number of treasury shares (own shares) held by the Company is 7.2% of the Company’s registered shares.

The New Shares were issued in relation to the sales agreement between the Company and Leerink Partners LLC (”Leerink Partners”)  entered into on May 8, 2024, with respect to an at-the-market (“ATM”) offering program. Under the ATM offering program, the Company may offer and sell, from time to time at its sole discretion, ordinary shares of the Company having an aggregate offering price of up to $100 million through Leerink Partners as its sales agent. The New Shares have not been sold under the ATM offering program and will be held in reserve as treasury shares.

For more details on the ATM offering program, please refer to the Company’s previous press release dated May 17, 2024, and the Company’s SEC filings referenced therein.

For more information, please visit:
http://www.oculis.com

Oculis Contact:

Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com 

Investor & Media Relations:

LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com 

1-212-915-2577

Staff

Recent Posts

BioLab Holdings, Inc. Announces Partnership with Real Collagen GmbH

Investment and Partnership will Allow Manufacturer to Create New Wound Care Products Using Fish Collagen…

5 hours ago

OsteoCentric Technologies Accepts UH Haslam Sports Innovation Center’s First Investment to drive Orthopedic Sports Medicine Innovation

AUSTIN, Texas, March 7, 2025 /PRNewswire/ -- OsteoCentric Technologies, a company dedicated to redefining Orthopedic…

5 hours ago

Waters Corporation to Present at the Leerink Partners Global Healthcare Conference

MILFORD, Mass., March 7, 2025 /PRNewswire/ -- Waters Corporation (NYSE: WAT) announced that Udit Batra…

5 hours ago

IDBS Unveils IDBS Polar Control: Revolutionizing Process Management in BioPharmaceutical Development

WOKING, United Kingdom, March 7, 2025 /PRNewswire/ -- IDBS, a leading global provider of cloud…

11 hours ago

Pharmacy Automation Market worth US$10.00 billion by 2030 with 7.1% CAGR | MarketsandMarkets™

DELRAY BEACH, Fla., March 7, 2025 /PRNewswire/ -- The global Pharmacy Automation Market, valued at…

11 hours ago

Hospital PMI® at 56%; February 2025 Hospital ISM® Report On Business®

TEMPE, Ariz., March 7, 2025 /PRNewswire/ -- Economic activity in the hospital subsector grew in February…

11 hours ago